Pharmaceutical firm Eris Lifesciences has received markets regulator Securities and Exchange Board of India’s (SEBI) approval to raise funds through an initial public offering (IPO). The IPO comprises 28.87 million shares through an offer for sale by ChrysCap and promoters. The company’s shares are proposed to be listed on the BSE and NSE.
The company had filed draft prospectus with Sebi in February and the markets regulator has issued final observation on the IPO papers on April 28. Listing will provide a public market for the equity shares in India. The lead managers for the issue are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: